We have modified the renal equations governing the rate of glucose excretion in the interactive homeostasis model assessment 2 (iHOMA2) model (1). On review of the equations describing the renal excretion, we noted that one of the coefficients was, in practice, redundant and could yield to misleading results. The renal excretion can adequately be described with three coefficients (R1, R2, and Rt)—instead of the previously reported four—which map to GFR, any element of sigmoidicity of the curve, and the renal threshold, respectively.

For clarity, we have abandoned R3 and R4 is redesignated “Rt.” Recalculating the data from our article, we estimate that to achieve the effects reported for dapagliflozin (2) Rt would be 58% and all other coefficients remain unchanged. These data were recalculated using the same phenotypically similar data set as used previously (3). We are currently planning to estimate the threshold effects of SGLT2 blockers using individual data.

The updated corrected model can be downloaded from http://www.ihoma.co.uk. Please quote the Revision number when reporting usage of the model. This should now be later than version 8.2.2.

1.
Hill
NR
,
Levy
JC
,
Matthews
DR
.
Expansion of the homeostasis model assessment of β-cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2
.
Diabetes Care
2013
;
36
:
2324
2330
2.
Komoroski
B
,
Vachharajani
N
,
Feng
Y
,
Li
L
,
Kornhauser
D
,
Pfister
M
.
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
.
Clin Pharmacol Ther
2009
;
85
:
513
519
3.
Cook
JT
,
Page
RC
,
O'Rahilly
S
, et al
.
Availability of type II diabetic families for detection of diabetes susceptibility genes
.
Diabetes
1993
;
42
:
1536
1543